Format

Send to

Choose Destination
J Hypertens. 2016 Feb;34(2):345-50. doi: 10.1097/HJH.0000000000000776.

Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.

Author information

1
aProfil Mainz RheinstrassebFirst Medical Department, Johannes Gutenberg University, Endocrinology LangenbeckstrassecFriedrich-Alexander-University, Interdisciplinary Centre for Ophthalmic Preventive Medicine and Imaging Schwabachanlage, Erlangen-NuernbergdProfil Institute for Metabolic Research, Hellersbergstrasse, Neuss, Germany.

Abstract

BACKGROUND:

Recent studies suggest vascular benefits of dipeptidylpeptidase IV (DPP-IV) inhibition in patients with diabetes mellitus. Only little is known about potential vascular effects of DPP-IV inhibitors in nondiabetic individuals. The aim of this study was to investigate the effect of DPP-IV inhibition in a nondiabetic hypertensive population.

METHOD:

This was a double-blinded, randomized, placebo-controlled, mechanistic study, comparing microvascular effects of the DPP-IV inhibitor linagliptin with placebo in nondiabetic individuals with a history of arterial hypertension. Twenty-one patients received 5 mg linagliptin (5 women; age 67.6 ± 6.0 years; mean ± SD), whereas 22 patients were randomized to placebo (5 women; age 64.8 ± 7.1 years).

RESULTS:

At baseline, after 6 and 12 weeks, retinal microcirculation and arterial blood pressure profiles were assessed. Moreover, blood samples were taken for the measurement of HbA1c, asymmetric dimethylarginine, C-reactive peptide, cyclic guanosinmonophosphate, transforming growth factor beta (TGF-ß1) and cystatin C. Retinal capillary perfusion increased by 23.7 ± 10.3% (mean ± SEM; P < 0.05), retinal arterial flow by 7.6 ± 0.6 (P < 0.05) and the retinal hyperemic response by 290 ± 263% (P < 0.05) during treatment with linagliptin. No change in retinal blood flow was found in the placebo group. Although blood pressure declined in both groups, a significant decline in TGF-ß1 by 9.3 ± 4.5% (P < 0.05) could only be observed in the linagliptin group. No significant change in other laboratory parameters could be observed in both groups.

CONCLUSION:

Our study suggests microvascular and antifibrotic effects of linagliptin in a nondiabetic, hypertensive population.

PMID:
26599219
DOI:
10.1097/HJH.0000000000000776
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center